Format

Send to

Choose Destination
Expert Rev Clin Pharmacol. 2014 May;7(3):235-8. doi: 10.1586/17512433.2014.890515. Epub 2014 Mar 3.

What are our pharmacotherapeutic options for MERS-CoV?

Author information

1
Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.

Abstract

Since the initial description of Middle East Respiratory Syndrome-coronavirus (MERS-CoV), the disease has been associated with a high case-fatality rate. There is a lack of proven effective medications for therapy of MERS-CoV. The current knowledge of therapeutic options for MERS-CoV is based on the experience from SARS-CoV and from in vitro studies. In this article we review the different therapeutics available for MERS-CoV from SARS experience, in vitro and animal studies of this emerging disease.

PMID:
24580083
DOI:
10.1586/17512433.2014.890515
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center